Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?

Group 1 - Ovid Therapeutics Inc. (NASDAQ:OVID) is recognized as a fast-growing penny stock, with analysts recommending it for investment, highlighted by LifeSci Capital initiating coverage with an Outperform rating and a price target of $4 [1] - The company announced successful Phase 1 results for OV350, the first direct activator of the KCC2 transporter tested in humans, achieving primary objectives with a favorable safety profile and no serious adverse events [2] - Ovid is shifting focus from OV350 to OV4071, an oral activator that is 20 times more potent, with plans to submit a regulatory application in Q1 2026 and initiate Phase 1/1b clinical trials in Q2 2026 for treating psychoses related to neurodegenerative conditions [3] Group 2 - Ovid Therapeutics is a biopharmaceutical company dedicated to developing medicines for patients with epilepsies and seizure-related neurological disorders in the US [4]